Potential New Role For Red Grape Seeds In Treatment Of Alzheimer's Disease
Mount Sinai researchers have discovered that polyphenolics derived from red grape seeds may be useful agents to prevent or treat Alzheimer's disease (AD). The new study entitled, "Grape derived polyphenolics prevent A^I^2 oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease, " was published in The Journal of Neuroscience.
Alzheimer's Society Comment On 'Charging Into Poverty?' UK
This report confirms the shocking truth that social care charges are hitting vulnerable older people harder than ever. There are 700, 000 people living with dementia in the UK and this will rise to over a million people in less than 20 years. What sort of society do we live in where people are forced to make huge sacrifices to pay for essential care? Dementia is not a natural part of getting older; it is caused by diseases of the brain and robs people of their lives.
New Booklet To Tackle Dementia Abuse
A new booklet to help care workers identify potential abuse in the dementia care environment will be released on World Elder Abuse Day, 15 June 2008. Developed by the Alzheimer's Society and Action on Elder Abuse, the booklet aims to help tackle abuse of people with dementia.
Ginkgo Biloba Does Not Help People With Dementia, Study Finds
Ginkgo biloba has no benefit for people with dementia, according to new Alzheimer's Society research. One of the longest and most rigorous studies yet on Ginkgo biloba found it does not slow progression of dementia and does not significantly effect cognitive function or quality of life. The study was the first to test the effects of Gingko biloba on people with dementia in a community setting in the UK and showed no significant benefit over a six month period.
Alzheimer's Symptoms And Depression Do Not Change Together
While there is a correlation between individuals with depression andthe development of Alzheimer's disease, it appears that the symptoms ofdepression do not increase in the years before an Alzheimer'sdiagnosis, according to a report released on April 7, 2008 in theJAMA/Archives journal Archives of General Psychiatry.
Teva's AZILECT R 1 Mg Tablets Meet End Points In ADAGIO Phase III Trial
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced the successful completion of ADAGIO, the phase III study designed to demonstrate that AZILECT 1 mg tablets can slow down the progression of Parkinson's disease. In the trial, the currently marketed AZILECT 1 mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical significance. The study also confirmed the safety and tolerability of AZILECT .
FDA Orders Older Antipsychotic Drugs To Carry Increased Warning Of Death Risks
The US Food and Drug Administration (FDA) flexed its new muscles yesterday, 16th June, and "ordered" manufacturers of older conventional antipsychotic drugs to strengthen the label so it warns about increased risk of death when the drugs are used off-label to treat older people with dementia. Under new powers granted in the Food and Drug Administration Amendments Act of 2007 (FDAAA), the agency can now order, rather than ask, the manufacturers to do this.
King's Fund Response To Commission For Social Care Inspection Report On Dementia Care, UK
Commenting on the Commission for Social Care Inspection's report See me, not just the dementia King's Fund Chief Executive Niall Dickson said: 'Over the next 20 years we are going to witness a dramatic increase in the number of people suffering from dementia. Unless there is a major breakthrough in drugs to arrest the course of this illness, there will be a great need for extra care and support, some of it quite intense.
Antipsychotics May Improve Psychiatric Symptoms In Alzheimer's Disease
Psychiatric and behavioral symptoms associated with Alzheimer's disease-such as anger, agitation, aggression, and paranoid thoughts and ideas-may improve with the use of second-generation antipsychotic medications, a new federally funded study has found. Improvements were seen both in global measures and in measures of specific symptoms. In addition, the analysis indicates that particular symptoms may respond better to different second-generation antipsychotic medications.
Alzheimer's Society Comment On CSCI Report 'See Me, Not Just The Dementia', UK
Neil Hunt, chief executive, Alzheimer's Society says, 'The standard of dementia care highlighted in this report is a national disgrace. 'Researchers have used a new way of looking at the real experiences or people living in care homes. It shows that half of the homes inspected needed to improve care with 155 statutory requirements and 191 recommendations for improvements being made.